Hepatitis C: New Treatment Helps Some, But Cure Remains Elusive PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Hepatitis C: New Treatment Helps Some, But Cure Remains Elusive PDF full book. Access full book title Hepatitis C: New Treatment Helps Some, But Cure Remains Elusive by John Henkel. Download full books in PDF and EPUB format.
Author: John Henkel
Publisher: DIANE Publishing
ISBN: 9781422326718
Category : Hepatitis C.
Languages : en
Pages : 18
Get Book Here
Book Description
Author: John Henkel
Publisher: DIANE Publishing
ISBN: 9781422326718
Category : Hepatitis C.
Languages : en
Pages : 18
Get Book Here
Book Description
Author: King K. Holmes
Publisher: World Bank Publications
ISBN: 1464805253
Category : Medical
Languages : en
Pages : 1027
Get Book Here
Book Description
Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.
Author:
Publisher:
ISBN:
Category : Consumer protection
Languages : en
Pages : 260
Get Book Here
Book Description
Author: Committee on Long-Term Care of Chimpanzees
Publisher: National Academies Press
ISBN: 0309591155
Category : Science
Languages : en
Pages : 108
Get Book Here
Book Description
Chimpanzees in biomedical and behavioral research constitute a national resource that has been valuable in addressing national health needs. Facilities that house chimpanzees owned and supported by the National Institutes of Health (NIH) have successfully met the research requirements of the scientific community. The captive chimpanzee population in the United States has grown substantially, particularly over the last decade. That growth is due primarily to the success of the NIH-sponsored Chimpanzee Breeding and Research Program, which achieved the birth numbers thought necessary to meet the projected needs of biomedical research. However, the expected level of use of the chimpanzee model in biomedical research did not materialize, and that has created a complex problem that threatens both the availability of chimpanzees for research in the future and the infrastructure required to ensure the well-being of captive chimpanzees used in biomedical research. Because the present system is fragmented, it is impossible to formulate an accurate overview of the size and nature of the chimpanzee population. But, if the chimpanzee is to continue to be used in biomedical research responsibly, effectively, and cost-effectively, we must be able to oversee, track, and coordinate the maintenance and use of chimpanzees and to control the size of the population. To assess the long-range situation and to develop, implement, and monitor the application of policies for the proper use and care of chimpanzees, an authoritative, centralized oversight structure is imperative. Once it is in place, it will be possible to refine and implement this report's recommendations.
Author: Albert J. Henry
Publisher: Moment LLC
ISBN: 0976388804
Category : Business & Economics
Languages : en
Pages : 494
Get Book Here
Book Description
A guide for people who aspire to practice as venture capitalists and also for those interested in gaining in-depth knowledge of the rigid system of venture capital. It explores the various aspects of venture capital investing. Almost 25% of venture capital companies are successful, while one third of them go bankrupt. Around 40% of these companies face difficulties coping with the growing economy. the companies in these different categories are respectively termed the good, the bad and the living dead.
Author:
Publisher:
ISBN:
Category : Law reports, digests, etc
Languages : en
Pages : 270
Get Book Here
Book Description
Author: David S. Hui
Publisher: European Respiratory Society
ISBN: 1849840709
Category : Medical
Languages : en
Pages : 148
Get Book Here
Book Description
Viral respiratory tract infections are important and common causes of morbidity and mortality worldwide. In the past two decades, several novel viral respiratory infections have emerged with epidemic potential that threaten global health security. This Monograph aims to provide an up-to-date and comprehensive overview of severe acute respiratory syndrome, Middle East respiratory syndrome and other viral respiratory infections, including seasonal influenza, avian influenza, respiratory syncytial virus and human rhinovirus, through six chapters written by authoritative experts from around the globe.
Author: Albert Henry
Publisher: Moment LLC
ISBN: 0976388812
Category : Business & Economics
Languages : en
Pages : 115
Get Book Here
Book Description
Walk into any hospital room and you are likely to find infusion pumps bearing the IMED or IVAC names. Stories of these companies convey themes typical of venture finance technological innovation driving higher valuations leading to a spectacular sale. (use italics in yellow/gold)These five broadly different case studies of major healthcare device companies and a biotechnology start-up to public company provide the reader with a rich cross section of business issues and answers. This book should be of interest to anyone in the health care industry, as well as to the general business reader. The cases provide a venture capitalist's and manager's view of how to start and build a company.The author was lead VC in each of these five companies. There is a detailed description of the issues and problems which occur in developing young companies to create significant value. The way problems and successes were dealt with gives the reader a broad learning experience ranging from the damage of patent infringement to being first in a market with runaway initial acceptance and learning how to keep the lead.Each of these cases comes from Henry Venture Fund investments. The reader learns how the investment opportunity was analyzed, how the investment was priced, how it was managed and directed into its product development and principal markets, and whether success or failure occurred and why. Two of the companies were sold for $400 million each, one was sold for $80 million in 22 months from founding, one declined in value by 90%, or $100 million, and was acquired and taken private and the the biotech company went public.Also included are two new biotech company descriptions which have made significant scientific discoveries. Sinapis Pharma has commenced a human clinical trial for brain trauma and stroke indications. TauTaTis is a preclinical company in Alzheimer's and Parkinson's Disease with very promising scientific data in mouse studies
Author: Joyce Brennfleck Shannon
Publisher:
ISBN:
Category : Liver
Languages : en
Pages : 614
Get Book Here
Book Description
This sourcebook contains basic consumer health information about the liver, how it works, and how to keep it healthy through diet, vaccination, and other preventative care measures.
Author: Ami Schattner
Publisher: Nova Publishers
ISBN: 9781600212017
Category : Medical
Languages : en
Pages : 392
Get Book Here
Book Description
This book discusses in detail new aspects of the metabolic basis of important chronic liver diseases. Entities such as non-alcoholic fatty liver disease (fatty liver and Non-Alcoholic SteatoHepatitis -- NASH), diabeties in chronic hepetitis C, hemochromatosis, Wilson's disease, Gaucher disease, porphyria, as well as liver cirrhosis and its metabolic consequences will be discussed in detail. These clinical conditions are highly prevalent and affect millions of patients in the USA and world-wide. For example, non-alcoholic fatty liver disease is the most common cause of elevated liver enzymes in the general population. This field has been practically transformed over the last few years, with many new insights gained, regarding both pathogenesis and effective novel treatments.
